Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc.

The latest announcement is out from Viatris ( ($VTRS) ). On June 17, 2026, Viatris Inc. completed a €650 million public offering of 4.250% senior u...

Viatris Issues €650 Million Senior Notes to Refinance Debt

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Viatris (VTRS), Medtronic (MDT) and Vertex Pharmaceuticals (VRTX)...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Viatris (VTRS), Medtronic (MDT) and Vertex Pharmaceuticals (VRTX)

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Viatris, with a price target of $12.00. Amsellem covers t...

Current Quarter	$0.62	Next Quarter	$0.66
Current Year	$2.47	Next Year	$2.7
QoQ Growth	+6.5%	YoY Growth	+9.3%
3Y EPS CAGR	-100.0%	Target Price	$18.22
Consensus	Buy	Upside	+18.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VTRS	$15.37	-2.29%	22.64M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VTRS	$15.37	-2.3%	22.64M
3
4
5
6

VTRS

VTRS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Viatris Inc. Data in Excel

Get Viatris Inc. Data in Excel